Previously recorded as Lion Biotechnologies, Inc. (to 2017)
144 patents currently held
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jun 2028. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
24
Ending by 2030
Jun 2028
Next term end
23
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jan 2038 · High confidence
Also notable
Ends Oct 2037 · Low confidence
Also notable
Ends Dec 2040 · Medium confidence
Also notable
Ends Apr 2041 · High confidence
Also notable
Ends Mar 2040 · High confidence
Also notable
Ends Sep 2039 · Low confidence
Also notable
Ends Oct 2037 · High confidence
Also notable
Ends Apr 2039 · High confidence
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same in Immunotherapy
US 10,166,257
Cited by 86 later US patents, top 5% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2038.
Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes
US 10,517,894
Cited by 77 later US patents, top 5% of utility patents granted in 2019 in our data. Protection runs to 2037. A terminal disclaimer caps this term to an earlier patent's.
Dual Cytokine Fusion Proteins Comprising IL-10
US 11,613,563
Cited by 13 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2040.
Systems and Methods for Coordinating Manufacturing of Cells for Patient-Specific Immunotherapy
US 11,631,483
Cited by 15 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2041.
IL-10 Variant Molecules Conjugated with Antibody Variable Domain Regions
US 10,981,966
Cited by 38 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2040.
Methods of Using Tumor Infiltrating Lymphocytes in Double-Refractory Melanoma
US 11,433,097
Cited by 31 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2039. A terminal disclaimer caps this term to an earlier patent's.
Engineered Artificial Antigen Presenting Cells for Tumor Infiltrating Lymphocyte Expansion
US 10,415,015
The most cited patent in this portfolio, cited by 100 later US patents, top 5% of utility patents granted in 2019 in our data. Protection runs to 2037.
Remnant Tumor Infiltrating Lymphocytes and Methods of Preparing and Using the Same
US 11,401,507
Cited by 23 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2039.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 30, 2027The maintenance fee for Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same in Immunotherapy (US 10,363,273) comes due Jan 30, 2027. Unpaid by Jul 30, 2027, it lapses early.
- 1 fee due Feb 1, 2027The maintenance fee for Processes for Generating Til Products Enriched for Tumor Antigen-Specific T-Cells (US 11,713,446) comes due Feb 1, 2027. Unpaid by Aug 2, 2027, it lapses early.
- 3 fees due Mar 3 to 24, 2027 · next Mar 3
- 2 fees due May 5 to 21, 2027 · next May 5
- 1 fee due Jun 30, 2027The maintenance fee for Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes (US 10,517,894) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 4 fees due Jul 2 to 21, 2027 · next Jul 2
- 1 fee due Sep 26, 2027The maintenance fee for Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same in Immunotherapy (US 11,939,596) comes due Sep 26, 2027. Unpaid by Mar 27, 2028, it lapses early.
- 1 fee due Oct 30, 2027The maintenance fee for Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes (US 11,969,444) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
- 5 fees due Nov 5 to 19, 2027 · next Nov 5
Recent changes
- 3 of the patents on this record were granted since Aug 22, 2026
What they patent
The largest of its 23 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,254,913 | Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same in Immunotherapy In force · Medium confidence | In force | Medium confidence | |
| US 11,939,596 | Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same in Immunotherapy In force · Medium confidence | In force | Medium confidence | |
| US 11,975,028 | Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes In force · Low confidence | In force | Low confidence | |
| US 11,998,568 | Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same in Immunotherapy In force · Low confidence | In force | Low confidence | |
| US 12,031,157 | Closed Process for Expansion and Gene Editing of Tumor Infiltrating Lymphocytes and Uses of Same in Immunotherapy In force · Medium confidence | In force | Medium confidence | |
| US 12,188,048 | Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes In force · Low confidence | In force | Low confidence | |
| US 12,194,061 | Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same in Immunotherapy In force · Medium confidence | In force | Medium confidence | |
| US 12,226,434 | Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same in Immunotherapy In force · Medium confidence | In force | Medium confidence | |
| US 12,226,522 | Processes for Production of Tumor Infiltrating Lymphocytes and Uses of the Same in Immunotherapy In force · Medium confidence | In force | Medium confidence | |
| US 12,280,140 | Processes for Production of Tumor Infiltrating Lymphocytes and Uses of the Same in Immunotherapy In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 144: 2 patents in force now held by others · 92 applications pending · 21 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.